Serum Paraoxonase 1 Activity Predicts Arterial Stiffness in Renal Transplant Recipients

Güngör, Özkan; Kırçelli, Fatih; Demirci, Meltem Seziş; Tuncel, Pınar; Şişman, Ali Rιza; Tatar, Erhan; Hür, Ender; Aşçı, Gülay; Ok, Ercan; Töz, Hüseyin

doi:10.5551/jat.9175

Cited by 15 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the potential role of PON1 in lipid transfer from LDL-C to HDL-C, it is likely that decreased serum PON1 activity is associated with the increased LDL-C in the olanzapine group. Interestingly, serum PON-1 activity is reported to be negatively correlated with serum LDL-C level 51,52. Furthermore, our finding of a positive correlation between serum PON1 activity and HDL-C level in the olanzapine group is of great interest.…”

Section: Discussionmentioning

confidence: 59%

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Ünsal¹,

Albayrak²,

Albayrak³

et al. 2013

NDT

View full text Add to dashboard Cite

BackgroundSecond generation antipsychotics (SGAs) are currently the most prescribed drugs in the treatment of schizophrenia. Despite their advantages, which include greater improvement in negative symptoms, cognitive function, prevention of deterioration, quality of life, and fewer extrapyramidal symptoms, the concern regarding metabolic abnormalities which might cause cardiovascular diseases during treatment with SGAs have been rising. Paraoxonase 1 (PON1) is an enzyme mostly located on high-density lipoprotein particles, and has been shown to protect or inhibit lipoprotein oxidation. Growing evidence suggests that PON1 plays a key role in the pathophysiology of atherosclerosis.MethodsIn the present study, we measured serum PON1 activity and serum levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in patients with schizophrenia, who had been treated with either olanzapine or quetiapine, and in healthy controls. Thirty five patients who had been treated with olanzapine, 29 patients who had been treated with quetiapine, and 32 age, sex, and smoking status-matched healthy control (HC) participants were enrolled. Serum PON1 activity and serum levels of TC, triglyceride, HDL-C, and LDL-C were measured.ResultsSerum PON1 activity in the olanzapine group was significantly lower than that of HC and quetiapine groups. Furthermore, serum levels of TC and LDL-C in the olanzapine group were significantly higher than those of quetiapine and HC groups. Interestingly, there was a positive correlation between PON1 activity and HDL-C levels in the olanzapine group.ConclusionThese findings suggest that serum PON1 activity in patients treated with olanzapine was lower than that of HC and quetiapine groups, and that PON1 may play a role in the metabolic side effects associated with olanzapine treatment. A further study to examine the relationship between serum PON1 activity and cardiovascular and metabolic side effects during treatment with SGAs will be of great interest.

show abstract

Section: Discussionmentioning

confidence: 59%

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Ünsal¹,

Albayrak²,

Albayrak³

et al. 2013

NDT

View full text Add to dashboard Cite

show abstract

“…measurement of ABCA1-mediated CEC is a direct index of HDL functionality strictly dependent on serum pre ␤ HDL content, as widely demonstrated ( 8,34,35,41 ), so it renders redundant HDL composition analyses such as HDL pre ␤ content measurement in the present study. The relationship between HDL composition/function and arterial stiffness seems to be underlined also by the recent observation that reduction of paraoxonase-1, an atheroprotective HDL antioxidant component, predicts PWV in renal transplant recipients ( 42 ). The demonstration that PWV in adulthood is infl uenced by atherogenic lifestyle factors in childhood ( 43,44 ) confi rms the existence of a large number of determinants, other than blood pressure and age, able to modify arterial wall over time in asymptomatic subjects.…”

Section: Resultsmentioning

confidence: 93%

ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects

Favari

Ronda

Adorni

et al. 2013

Journal of Lipid Research

View full text Add to dashboard Cite

“…Previous studies of renal transplant populations revealed that recipient and donor age, hypertension, duration of dialysis, diabetes, and acute rejection were related to increased arterial stiffness [7,13]. In addition, lower serum magnesium [14] and paraoxonase 1 activity [15] have been reported to be independently associated with arterial stiffness. Our results show a similar association between low pre-transplant serum adiponectin level and arterial stiffness, and that those levels are associated with development of NODAT.…”

Section: Discussionmentioning

confidence: 99%

Low serum adiponectin level is predictor of arterial stiffness in new onset diabetes after renal transplantation

Nishimura¹,

Hirai²,

Nakazawa³

et al. 2012

JDM

View full text Add to dashboard Cite

Background: The purpose of this study was to determine whether the level of adiponectin in serum of renal transplant patients is associated with arterial stiffness related to new onset diabetes after transplantation (NODAT). Methods: A total of 90 previously non-diabetic patients who underwent renal transplantation between 1999 and 2009 were enrolled. We evaluated their diabetic risk factors, lipid profiles, brachial-ankle pulse wave velocity (baPWV), ankle-brachial blood pressure index (ABPI) and serum adiponectin level before and after transplantation. Results: Eleven (12.2%) patients were diagnosed with NODAT and 79 (87.8%) without (non-NO-DAT). The mean post-transplant serum adiponectin level in NODAT patients was significantly lower than that in non-NODAT patients (11.9 vs. 16.4 μg/ml, p = 0.01), whereas the mean baPWV level in NODAT patients was significantly higher (1686 vs. 1468 cm/s, p = 0.016). We found a significant inverse correlation between mean pre-transplant serum adiponectin and baPWV level (r = −0.27, p = 0.011). Furthermore, patients with lower pretransplant serum adiponectin levels (<20 μg/ml) developed NODAT significantly more frequently than those with higher levels (p = 0.038) and the mean baPWV level in the former was also significantly higher (1520 vs. 1412 cm/s, p = 0.047). Conclusion: Our results indicate that low pretransplant serum adiponectin level is associated with arterial stiffness in development of NODAT in patients who undergo renal transplantation.

show abstract

Serum Paraoxonase 1 Activity Predicts Arterial Stiffness in Renal Transplant Recipients

Cited by 15 publications

References 23 publications

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine

ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects

Low serum adiponectin level is predictor of arterial stiffness in new onset diabetes after renal transplantation

Contact Info

Product

Resources

About